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Background: Although various empiric adjunctive ablation techniques are widely performed with
pulmonary vein antrum isolation (PVAI) to enhance the procedural efﬁcacy of catheter ablation in non-
paroxysmal atrial ﬁbrillation (NPAF) patients, they are not required in all NPAF patients.
Methods and results: Eighty consecutive NPAF patients refractory to antiarrhythmic drugs underwent a
PVAI-based ablation. Structural heart disease was present in 40% of patients and systolic dysfunction in
21%. After 31±16 months of follow-up, 41% of the patients were free of atrial tachyarrhythmia recurren-
ces after a single procedure. Finally, during a mean follow-up of 25±15 months, 63 of 80 (79%) patients
remained in sinus rhythm (SR) after the ﬁnal procedure (two procedures in 48%, and three in 3%). A Cox
regression multivariate analysis revealed that left atrial volume (LAV) was the only independent predic-
tor of atrial tachyarrhythmia recurrences not only after single procedures (p=0.027), but also after the
ﬁnal procedures (p=0.001). Ten patients (13%) needed ablation for concomitant atrial tachycardias origi-
nating from the left atrium and right atriumother than common atrial ﬂutter. Repeat ablation procedures
increased the best cut-off value for predicting recurrences analyzed by receiver operating characteristic
curves, from 86mL (sensitivity 70%, speciﬁcity 64%) to 92mL (sensitivity 71%, speciﬁcity 78%).
Conclusions: PVAI-based ablation strategies could achieve SRmaintenance in almost 80% of NPAF patients
aftermultipleproceduresduring long-term follow-up. Thepreprocedural LAVwasan importantpredictor
of the procedural outcome.
3 Jap© 201
ntroduction
Various empiric adjunctive ablation techniques, such as com-
lex fractionated atrial electrogram ablation, left atrial (LA) linear
esions, and ganglionated plexi (GP) ablation, have been devel-
ped to enhance the procedure efﬁcacy of the catheter ablation
f atrial ﬁbrillation (AF). However, the role of additional empiric
ubstrate modiﬁcation beyond pulmonary vein (PV) antrum iso-
ation (PVAI) in patients with non-paroxysmal AF (NPAF) remains
ontroversial [1–5]. At least, such additional ablation methods are
∗ Corresponding author. Tel.: +81 3 3353 8111; fax: +81 3 3356 0441.
E-mail address: koichiro@qf6.so-net.ne.jp (K. Ejima).
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not required in all patients with NPAF [6]. On the other hand, there
are few reports on the long-term outcome of PVAI-based strategies
without additional empiric substrate modiﬁcation in a population
containing only patients with NPAF [7].
The aim of this study was to clarify the long-term outcome and
thepreprocedural predictors of atrial tachyarrhythmia (ATA) recur-
rence after a PVAI-based ablation strategy in NPAF patients.
MethodsStudy population
This study included 80 consecutive patients who underwent
catheter ablation for symptomatic, drug-refractory NPAF and who
vier Ltd. All rights reserved.
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ere observed for at least 6months following the last ablation pro-
edure. All patients underwent a PVAI-based ablation. Persistent
F (PerAF) and long-standing persistent AF (LPAF) were deﬁned
ccording to the HRS/EHRA/ECAS 2007 Consensus Statement on
atheter and Surgical Ablation of AF [8]. All patients gave their
ritten informed consent.
reprocedural evaluation and management
As a preoperative evaluation, all patients underwent trans-
horacic echocardiography (TTE), trans-esophageal echocardiog-
aphy (TEE), and multi-detector computed tomography (MDCT)
sing a 64-slice CT scanner within 2 days prior to the scheduled
blation procedure. All echocardiographic parameters were mea-
ured according to the recommendations of the American Society
f Echocardiography [9]. The left atrial volume (LAV)wasmeasured
n the standard four- and two-chamber views. The end-systolic
AV was measured in each view using the modiﬁed Simpson’s
ule. The MDCT image was obtained with contrast enhancement
n most patients, but without contrast enhancement in those with
enal dysfunction. All patients were effectively anticoagulated for
1 month, and TEE was performed to exclude any LA thrombi prior
o the ablation procedure. Before the procedure, all antiarrhythmic
rugs (AADs) were discontinued for at least 5 half-lives except for
miodarone. Anticoagulation therapy using warfarin with a ther-
peutic international normalized ratio was continued during the
eriprocedural period.
apping and ablation protocol
All patientsunderwent awidePVAI guidedbyelectroanatomical
apping combined with image integration [10]. A 3.5-mm cooled-
ip catheter (Navistar ThermoCool or ThermoCool SF, Biosense
ebster Inc., Diamond Bar, CA, USA) was utilized for mapping and
blation. The circumferential ablation lines were created approxi-
ately 2–4 cm from the ipsilateral PV ostia except for the anterior
spect of the left PVs. PV isolation was conﬁrmed by the elec-
rograms recorded from circular mapping catheters and pacing
aneuvers. Radiofrequency (RF) energy was delivered to the atrial
issue with a power of 25–30W using irrigation rates of 17mL/min
ith the Navistar ThermoCool or 8mL/min with the Navistar Ther-
oCool SF to achieve the desired power delivery. The power was
imited to 20–25W at the posterior wall of the LA. The tempera-
ure was limited to 42 ◦C. After a successful wide PVAI, we tried to
rovoke a reconnection of the PVs (dormant PV conduction) with
20mg intravenous rapid injection of ATP administered under a
0g bolus injection of intravenous isoproterenol during sinus
hythm (SR) or CS pacing. If any dormant PV conduction was
bserved, additional RF energy was applied at the earliest PV acti-
ation site identiﬁed using the circular mapping catheters on the
ircumferential ablation lines, until the loss of any dormant PV con-
uction.AnadministrationofATPwasgivenat least20minafter the
solation of each PV [11]. If AF was sustained at the start of the abla-
ion procedure, SR was restored by electrical cardioversion prior to
he ablation. If cardioversion failed to restore SR, the PVAI was per-
ormed inAFandcardioversionwasattempted later. Frequent atrial
rematurebeats inducedbya10gbolus injectionof isoproterenol
ere attempted to be abolished by a focal ablation of a speciﬁc
rigin or a superior vena cava (SVC) isolation for an SVC origin.
avotricuspid isthmus (CTI) ablation was performed for common
trial ﬂutter, which was clinically documented or induced during
he procedure. We targeted the ablation of any ATAs, except for
F, induced by programmed electrical stimuli (PES) with/without
soproterenol. If AF was induced by the PES, we performed an elec-
rical cardioversion to restoreSRandﬁnished theprocedure.During
nd after the second ablation session in the patients with ATAiology 64 (2014) 57–63
recurrences after the index procedure, the previously delivered
lesions were evaluated. If necessary, a re-isolation of the PVs and
SVC, CTI ablation, focal ablation of frequent atrial premature beats,
and ablation of any ATAs other than AF were performed.
Postablation follow-up
Ineffective AADs before the ablation were prescribed only if any
early recurrences of an ATA were observed prior to discharge in
patients with perAF. In patients with LPAF, discontinuation of the
AADs was recommended 3 months after the ablation. The AADs
for coexisting ventricular tachycardia in patients with structural
heart disease (SHD) were continued. All patients were scheduled
for visits in the outpatient clinic at 1, 2, 3, 6, 9, and 12 months after
the ablation procedure and then every 6 months. The presence of
AF was evaluated by the patient symptoms, electrocardiographic
recordings, and 24-h ambulatory monitoring (1, 3, 6, 9, and 12
months after the ablation and then every 6 months). Patients with
palpitations were encouraged to use portable electrocardiographic
monitoring (HCG-801R; Omron, Kyoto, Japan). Recurrence was
deﬁned as recurrent symptoms and/or documented ATAs on the
electrocardiogram, 24-h ambulatory monitoring, portable electro-
cardiographic monitoring, or cardiac rhythm management device
(lasting >30 s) after a 2-month blanking period from the ablation
procedure. In the absence of any AF recurrences after 6 months,
the anticoagulant treatment was discontinued unless the patients
had a CHADS2 score of ≥2. The minimum follow-up of this series
was 6 months after the ﬁnal ablation procedure.
Statistical analysis
Data are presented as the mean± SD, percentage, or number,
as appropriate. Differences between the continuous values were
assessed using an unpaired 2-tailed t-test for normally distributed
continuous variables, theMann–Whitney test for skewedvariables,
and the 2 test for nominal variables. A Cox proportional hazards
model was used to identify any preprocedural predictors of ATA
recurrences after single and repeat ablation procedures. All prepro-
cedural potential confounders were entered into the model on the
basisof knownclinical relevanceor signiﬁcantassociationobserved
in the univariate analysis. All parameters with a signiﬁcance of
<0.05 in the univariate analysis were entered into the multivari-
ate model. If more than 2 of the indices of the LA size, including
the LA dimension, LAV, and LAV index, exhibited a p<0.05 in the
univariate analysis, we chose one of them, which had the lowest
p-value among them, as one of the variables for the multivariate
analysis. To obtain the best cut-off value of any predictor for an
ATA recurrence after the ablation procedure, a receiver-operating
characteristic (ROC) curve was generated and the area under the
curve (AUC) was calculated. A Kaplan–Meier analysis with a log-
rank test was used to determine the probability of the freedom
from recurrent ATAs after the initial and last procedure. A p-value
<0.05 was considered statistically signiﬁcant. All statistical analy-
ses were performed with JMP software version 10.0 (SAS Institute,
Cary, NC, USA).
Results
Patient characteristics
The baseline patient characteristics are shown in Table 1. Of 80
NPAF patients, 15 (19%) had LPAF. The median value (interquartile
range) of theAFdurationwas4 (1–8)months inpatientswith PerAF
and 30 (17–39) months in patients with LPAF. Thirty-two (40%)
patients had SHDs including 11 with hypertrophic cardiomyopa-
thy, 8 with dilated cardiomyopathy, 4 with dilated hypertrophic
K. Ejima et al. / Journal of Cardiology 64 (2014) 57–63 59
Table 1
Patient characteristics.
N 80
Age (years) 59±9
Sex: male, n (%) 69 (86)
Type of AF
Persistent AF, n (%) 65 (81)
Long-standing persistent AF, n (%) 15 (19)
AF duration (month), median (IQR) 5 (1, 12)
AF history (month), median (IQR) 60 (25, 93)
CHADS2 score 0.9±0.8
Hypertension, n (%) 36 (45)
Diabetes mellitus, n (%) 15 (19)
Structural heart disease, n (%) 32 (40)
Sleep apnea syndrome, n (%) 10 (13)
Body mass index (kg/m2) 24.3±3.1
Estimated glomerular ﬁltration rate (mL/min/1.73m2) 66.1±16.6
BNP (pg/mL) 201.2±256.6
LA dimension (mm) 44±7
LA volume (mL) 83±29
LA volume index (mL/m2) 47±18
LV end-diastolic diameter (mm) 49±8
LV end-systolic diameter (mm) 36±9
LVEF (%) 48±12
LVEF less than 40%, n (%) 17 (21)
Ineffective antiarrhythmic drugs 1.9±1.2
Amiodarone use, n (%) 27 (34)
Cardiovascular implantable electronic devices, n (%) 11 (14)
AF, atrial ﬁbrillation; IQR, interquartile range; BNP, brain natriuretic peptide; LA, left
atrial; LV, left ventricular; LVEF, left ventricular ejection fraction.
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Table 2
Ablation procedures.
1st session n=80
PVAI 80 (100)
CTI linear ablation 32 (40)
SVC isolation 6 (8)
LAAW localized reentrant AT 1 (1)
CSOS focal AT 1 (1)
LSPV-LAA ridge dependent macro reentrant AT 1 (1)
RA free wall macro reentrant AT 1 (1)
2nd session n=38 (48%)
PVI 36 (95)
CTI linear ablation 15 (40)
SVC isolation 13 (34)
Other non PV foci 1 (3)
PMFL 6 (16)
Gap-gap macroreentrant AT 2 (5)
Roof dependent macroreentrant AT 1 (3)
LAAW focal AT 1 (3)
LAPW focal AT 1 (3)
3rd session n=2 (3%)
PVI 1 (50)
PMFL 2 (100)
LAAW AT 1(50)
n (%).
PVAI, pulmonary vein antrumisolation; PVI, pulmonary vein isolation; CTI, cavo-
tricuspid isthmus; SVC, superior vena cava; LAAW, left atrial anterior wall;
CSOS, coronary sinus ostium; LSPV, left superior pulmonary vein; LAA, left atrial
Eleven ATs were recognized during the second procedure in 8
patients including 2 focal ATs (on the anterior and posterior wall
of the LA) and 9 macro-reentry ATs [6 peri-mitral ﬂutters (PMFL),
2 gap–gap macroreentrant ATs, and 1 roof dependent AT]. All ATsardiomyopathy, 4 with status post cardiac valvular replacement
urgery, 2 with old myocardial infarctions, and 3 with other car-
iomyopathies. Seventeen (21%) patients had systolic dysfunction,
nd a left ventricular ejection fraction of less than 40%. Eighteen
23%) patients had coexisting ventricular tachycardia. Twenty-
even (34%) patients were resistant to amiodarone. Eleven (14%)
atients were implanted with cardiovascular implantable elec-
ronic devices including 9 with cardiac resynchronization therapy
eﬁbrillators, 1 with a dual-chamber implantable cardioverter
eﬁbrillator, and 1 with a dual-chamber pacemaker.
rocedures performed during the ﬁrst ablation procedure
Thedetails of the ablation procedures performedduring theﬁrst
rocedure are shown inTable 2. All patients underwent awidePVAI
ndall PVswere successfully isolated. Four atrial tachycardias (ATs)
ere induced during the ﬁrst procedure in 3 patients including 2
ocal ATs (at the anterior wall of the LA and ostium of the coronary
inus) and 2macro-reentry ATs (1 from the RA freewall, and 1 from
he ridge between the left superior PV and left atrial appendage).
ll ATswere successfully terminatedduring theRF applications and
ere no longer inducible.
ong-term outcome after a single ablation procedure
During a mean follow-up of 31±16 months, 33 of 80 (41%)
atients remained in SR after a single procedure, including 7
atients taking AADs (5 amiodarone, 1 bepridil, and 1 ﬂecainide)
Figs. 1 and 2). Atrial tachyarrhythmias recurred in 47 of 80 (59%)
atients (4 paroxysmal AF, 13 persistent AF, 3 paroxysmal AT, and 7
ersistent AT). Four patients refused any further efforts for rhythm
ontrol and discontinued taking their AADs. An ATA recurrence
ccurred within 3 months, 6 months, and 1 year after ablation in
1 (45%), 28 (60%), and 40 (85%) patients, respectively.appendage; AT, atrial tachycardia; RA, right atrial; PMFL, perimitral ﬂutter; LAPW,
left atrial posterior wall.
Procedures performed during the repeat ablation procedure and
the long-term outcome after multiple procedures
Thirty-eight (48%) patients underwent a second procedure
(Fig. 1 and Table 2). The second ablation procedure was performed
a mean of 14±12 months after the index procedure. During the
second procedure, recovered LA-PV conduction was found in 36
of 38 (95%) patients and was re-isolated in all patients. A non-PV
trigger of AF on the LA septum near the upper limb of the foramen
ovale was abolished.Fig. 1. Flow chart of the clinical outcome after multiple procedures. pts, patients;
SR, sinus rhythm; AAD, anti-arrhythmic drug.
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.ig. 2. Kaplan–Meier curves of the maintenance of sinus rhythm after a single and
ultiple ablation procedures. AF, atrial ﬁbrillation; AT, atrial tachycardia.
xcept for some PMFLs were successfully terminated during the RF
pplicationsandwereno longer inducible. Bidirectional conduction
lock of the mitral isthmus (MI) could be achieved only in 1 of 6
atients with PMFL.
After the second procedure, 28 patients could be maintained
n SR, including 10 patients that were taking AADs (7 amiodarone,
bepridil, and 1 ﬂecainide) (Fig. 1). ATAs recurred in 10 patients
5 with paroxysmal AF, 3 with persistent AF, and 2 with persistent
T). Two patients abandoned the rhythm control and discontinued
aking their AADs. Among the patients with ATA recurrences after
he second procedure, 2 patients with recurrence of the persistent
T underwent a third procedure 68 and 96 days after the second
rocedure, respectively (Fig. 1 and Table 2). Both patients under-
ent MI linear ablation for PMFL and one patient underwent a PV
e-isolation for an LA-PV reconduction in the right PV.
Finally, during a mean follow-up of 25±15 months, 63 of
0 (79%) patients remained in SR, including18patients takingAADs
12 amiodarone (113±43mg/day), 3 bepridil, 2 ﬂecainide, and 1
ibenzoline] (Fig. 2). Among the patients taking AADs, 7 were tak-
ng themforventricular tachycardia. In17patientswith recurrence,
refused any further efforts to maintain SR and accepted the AF
hythm.Other recurrent arrhythmiaswereparoxysmalAF in 8, per-
istent AF in 1, and persistent AT in 1. Overall, in total 10 of 80 (13%)
atients underwent catheter ablation of concomitant ATs. Five of
he 7 patients with PMFL had a large LA exceeding an LAV of more
han 110mL.
No major complications occurred during the periprocedural
eriod or follow-up period in this study.
reprocedural predictors of atrial tachyarrhythmia recurrences
fter a single procedure
To analyze the predictors of ATA recurrences, both univariate
nd multivariate analyses were performed (Table 3). In the multi-
ariate analysis, the LAV (OR 1.01, 95% CI; 1.002–1.027, p=0.027)
as the only independent predictor of an ATA recurrence after a
ingle ablation procedure. The ROC curve with the LAV (AUC; 0.70,
= 0.0016) used to predict ATA recurrences after a single abla-
ion procedure revealed that an LAV >86mL was the best cut-off
alue for predicting a recurrence after a single ablation procedure
accuracy 69%, sensitivity 57%, speciﬁcity 85%, PPV 84%, and NPV
8%). TheATArecurrence-free survivalprobabilitywas signiﬁcantly
igher in the patients with an LAV <86mL when compared to those
atients with an LAV >86mL (p=0.0001) (Fig. 3A). All the patients Ta
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Fig. 3. Kaplan–Meier curves of the maintenance of sinus rhythm after a single abla-
tion procedure (A) and after multiple ablation procedures (B); in all patients, and
(C); among the patientswho underwent repeat procedures. The atrial tachyarrhyth-
mia recurrence-free survival probability signiﬁcantly differed between the 2 groups
dichotomized by the cut-off value of the left atrial volume, which was detected
b
r
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w
p
P
p
py a receiver operating characteristic analysis to predict recurrence after single and
epeat ablationprocedures, respectively. AF, atrial ﬁbrillation;AT, atrial tachycardia;
AV, left atrial volume.
ith an LAV >110mL had ATA recurrences after a single ablation
rocedure (Fig. 4A).
redictors of atrial tachyarrhythmia recurrence after repeat
rocedures
In the multivariate analysis, the LAV (OR 1.04, 95% CI 1.02–1.06,
= 0.001)was the only independent predictor of an ATA recurrenceiology 64 (2014) 57–63 61
after the ﬁnal ablation procedure (Table 3). The ROC curve using
the LAV (AUC 0.78, p=0.0005) to predict ATA recurrences after the
ﬁnal ablation procedure revealed that an LAV >92mL was the best
cut-off value for predicting a recurrence after the ﬁnal ablation
procedure (accuracy 76%, sensitivity 71%, speciﬁcity 78%, PPV 46%,
NPV 91%). The ATA recurrence-free survival probability was signif-
icantly higher in the patients with an LAV <92mL when compared
to the patients with an LAV >92mL (p<0.0001) (Fig. 3B). Repeat
ablation procedures increased the best cut-off value for predicting
a recurrence analyzed by the ROC curve was from 86mL to 92mL.
We then tried to analyze the predictors of ATA recurrences
after multiple procedures only among the patients that underwent
repeat procedures (Table 3). In the multivariate analysis, the LAV
(OR 1.03, 95% CI 1.002–1.060, p=0.037) was the only independent
predictor of an ATA recurrence after the ﬁnal ablation procedure.
The ROC curve using the LAV (AUC 0.74, p=0.045) to predict an
ATA recurrence after the ﬁnal ablation procedure revealed that an
LAV >72mL was the best cut-off value for predicting a recurrence
after the ﬁnal ablation procedure (accuracy 55%, sensitivity 100%,
speciﬁcity 43%, PPV 32%, NPV 100%). The ATA recurrence-free sur-
vival probability was signiﬁcantly higher in the patients with an
LAV <72mL when compared to those patients with an LAV <72mL
(p=0.016) (Fig. 3C). The patients with an LAV <72mL (n=13) had
no recurrence of ATAs after the ﬁnal procedure (only 2 with AADs)
(Fig. 4C).
Discussion
Main ﬁndings
In this study, we clariﬁed the relatively long-term outcome of a
wide PVAI-based ablation strategy in patients with NPAF and the
preprocedural predictors of ATA recurrences after the procedure.
The main ﬁndings were as follows: (1) during a mean follow-up of
31±16 months, our ablation strategy allowed 41% of the patients
to remain in SR after a single procedure. Finally, during a mean
follow-up of 25±15 months, 79% of the patients remained in SR
after multiple procedures. (2) The LAV was the only independent
predictor of a recurrence not only after a single procedure but also
after multiple procedures. An LAV >86mL (sensitivity 70%, speci-
ﬁcity 64%) and LAV >92mL (sensitivity 71%, speciﬁcity 78%) were
the best cut-off values for predicting a recurrence after the ﬁrst and
ﬁnal ablation procedures, respectively.
Catheter ablation strategy based on a wide PVAI without any
empiric additional substrate modiﬁcation in patients with NPAF
The development of the 3D electro-anatomical mapping tech-
nology, in particular the use of image integration, made it possible
to achieve accurate and wide encircling lesions around the PV
antrum [12]. PVAI has been considered to have several advantages
for maintaining SR as compared to a simple PVI. The PVAI excludes
the triggers/initiators and perpetuators not only in the PVs but also
in the PV antrum,which has similar arrhythmogenic activity to that
of the PVs, and in the LA posterior wall [13]. Further, the debulking
of the LA by a wide PVAI line modiﬁes the substrate responsible for
the large and small reentrant wavelets that play a role in initiating
and sustaining AF [14]. Furthermore, a recent study demonstrated
the effect of PVAI on decreasing the area of CFAEs [15] and elimi-
nating the GP response [16].
The role of an additional ablation strategy beyond the PVAI in
patientswithNPAF remains controversial [1–5]. At least, such addi-
tional ablation strategies are not necessarily required in all patients
with NPAF [6]. An additional ablation strategy including an LA lin-
ear ablation with bidirectional block, and ablation of the CFAE and
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rig. 4. Procedural outcome and the distribution of the preprocedural left atrial vol
ultiple procedures only among the patients that underwent repeat procedures (C)
rocedure; Rec−, patients who had no recurrence after a single/repeat ablation pro
P areas are still challenging, time consuming, and have the poten-
ial to lead to an iatrogenic AT after the ablation procedure [17].
reprocedural information about the predictors of recurrence after
PVAI-based strategy in patients with NPAF is useful to select the
atients who need an aggressive ablation strategy.
mportance of the LAV as a predictor of atrial tachyarrhythmia
ecurrences after ablation of atrial ﬁbrillation
LA enlargement is associated with structural remodeling due
o AF and promotes the occurrence of AF (AF begets AF). Exten-
ive evidence implicates atrial remodeling as an important player
n the pathophysiology of AF. Recently, a series of studies have
emonstrated that the LAV is one of the strongest predictors of the
utcome followingAFablation [18–25]. Further, the LAV is reported
s a better predictor of the AF ablation outcome than the LAD [25].
prior study described the importance of the LAV as a predic-
or of a recurrence after AF ablation which included patients with
AF [18–25], and the ablation strategy was not necessarily uniform
18,20,24]. This study clariﬁed the importance and cut-off value of
he preprocedural LAV as a predictor of a recurrence not only after
single procedure but also after multiple procedures that applied
uniﬁed ablation strategy, that is, a wide PVAI-based ablation, in a
opulation containing only patientswithNPAF. Further, the follow-
p period in the present study (mean, 31 months) was longer than
hat in the previous studies (mean, 6–19 months).
linical implications
A PVAI-based ablation for NPAF provides good long-term AF
ontrol in almost 80% of patients. A repeat ablation procedure and
ADs were often necessary to obtain this favorable outcome. The
reprocedural LAV was the independent predictor of an ATA recur-
ence. The results of this study will help us to improve our patientAfter a single procedure (A), after multiple procedures in all patients (B), and after
, patients who had atrial tachyarrhythmia recurrences after a single/repeat ablation
e. Red dot, with anti-arrhythmic drugs; blue dot, without anti-arrhythmic drugs.
selection for this ablation strategy and consider the candidates for
additional ablation procedures.
Limitations
Our study had several limitations. First, the study population
was relatively small. Second, this was a single-center study. Third,
the recurrence rate of AF may have been underestimated because
asymptomatic AF episodes may have been undetected. Fourth, not
all the patients with PMFL achieved a successful MI linear ablation
with bi-directional block. Making a complete block line along the
MI might have increased the ratio of the SR maintenance in this
study [26].
Conclusion
APVAI-based ablation strategy could achieve SRmaintenance in
almost 80% of patients with NPAF after multiple procedures in the
long-term follow-up. The preprocedural LAV obtained by 2D TTE
yielded valuable information about the procedural outcome.
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